Florbetaben

Florbetaben (also known as Neuraceq or BAY94-9172) is a radiopharmaceutical compound used in positron emission tomography (PET) imaging. It is a derivative of the Amyloid protein and is used to detect Beta-amyloid plaques in the brains of patients suspected of having Alzheimer's disease.

History

Florbetaben was developed by the German company Bayer Schering Pharma. The compound was first introduced in 2005 and received approval from the European Medicines Agency (EMA) in 2014. It is now marketed under the brand name Neuraceq.

Mechanism of Action

Florbetaben works by binding to beta-amyloid plaques in the brain, which are a hallmark of Alzheimer's disease. The compound is labeled with the radioactive isotope Fluorine-18, which allows it to be detected by PET imaging.

Clinical Use

Florbetaben is used in PET imaging to detect the presence of beta-amyloid plaques in the brains of patients suspected of having Alzheimer's disease. It is not a cure for the disease, but it can help in the diagnosis and monitoring of the condition.

Side Effects

Common side effects of Florbetaben include headache, nausea, and injection site reactions. In rare cases, it can cause serious allergic reactions.

See Also

• Alzheimer's disease
• Beta-amyloid
• Positron emission tomography
• Radiopharmaceutical

Florbetaben Resources
Latest articles Most recent articles Ongoing trials	Wikipedia